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84 Objectives and Methodology of the Consensus Process
Finally, in the course of developing this document,
it became clear that in some key areas no strong opin-
ions are held because of absence of sufficient relevant
hard data. These "Critical Issues" have been identified
as such in the document. Consensus documents such
as this must, of necessity, be ephemeral. The scientific
process was completed in the middle of 1999 and rep-
resents the up-to-date view at that time. It must be
accepted that further evidence will make some of the
conclusions in the document out of date and incorrect
in subsequent years. The participating societies there-
fore commit themselves to continuing the update
process (Figure 1).
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A2
EPIDEMIOLOGY, NATURAL HISTORY,
RISK FACTORS
A2.1
Introduction to Epidemiology
The management of the patient with peripheral arteri-
al disease (PAD) has to be planned in the context of the
epidemiology of the disease and, in particular, the
apparent risk factors or markers predicting sponta-
neous deterioration. It is also necessary to know the
magnitude of the problem together with the likely
outcome in patients with differing severity of PAD to
analyse outcome measures and to assess the socioeco-
nomic impact of the disease. A detailed search of all
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the relevant publications was performed for this chap-
ter. The resulting full analysis of the data has been
published separately in Seminars ill Vascular Surgery.l
A full list of references and complete tables of data
also can be found in that publication. Those tables are
the basis for the summary figures and diagrams repro-
duced in this document.
A2.2
Intermittent Claudication
A 2.2.1
The Problem of Defining Intermittent Claudication
Intermittent claudication (IC) is usually diagnosed by
a history of leg pain on exercise that is relieved by rest.
Several questionnaires have been developed for epi-
demiological use. Other diagnostic methods include
interview, clinical examination, and noninvasive tests.
In looking at methods for identifying IC in the popu-
lation, it must be remembered that it is merely a symp-
tom of PAD and that the measurement of symptoms is
notoriously difficult. A patient with quite severe PAD
may not have the symptom of IC because some other
condition limits exercise. Likewise, patients with very
mild PAD may have symptoms of IC if they are very
active.
Questiollllaires
The WHO/Rose Questionnaire has been the most
widely used cardiovascular questionnaire for the
identification of patients with Ie. It was designed in
1962 by Rose,2 was subsequently adopted by the
WHO, and has been widely used to estimate the preva-
lence of intermittent claudication.s In one survey in a
large population in France, this questionnaire was
shown to be highly specific (99.8%) in excluding
healthy individuals but only moderately sensitive
(67.5%) in detecting those with claudication compared
with physicians' assessments of symptoms (Table 1}.3
In other words, there were only 0.2% false; false posi-
tives are questionnaire-positive individuals who were
not patients with intermittent claudication) but 32.5%
false negatives (false negatives are patients with inter-
mittent claudication who were questionnaire nega-
tive). The classification was extended in 1985 to
include "possible.claudicants" (ie, those patients with
exercise leg pain that is not present at rest, but who are
not otherwise fully concordant with the Rose criteria)
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Tabl e 1. Diagnost ic performance of various techniques for defining IQPAD
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WHO/Rose questionnaire
Rose, 19622
Richard et al, 19723
lsacsson , 19722.'
Criqui et al, 19851
Edinburgh questionnaire
Leng & Fowkes, 1992;
lVHO/Rosc qllcsliollllaire and ABPI < 0.9
Criqui ct al, 1985~
Ogren et al, 1993="
' Probable claudication "Possible claudication
Sensitivity (%)
92
67.5
30
9'
20"
91
71.2
15
Diagnostic performance
Specificity (%)
100
99.8
98
99'
95.9"
99
91.3
98
to try to improve the questionnaire's sensitivity, but at
the expense of a slight decrease in specificity,'
The Edinburgh Claudication Questionnaire is
designed to be self-administered." The main differ-
ences compared with the WHO/Rose questionnaire
are i) patients answering negatively to leg pain or dis-
comfort when walking do not continue with the ques-
tionnaire and ii) the patient is asked to mark the
place(s) of the pain on a diagram. This questionnaire
was validated in a study of approximately 300 patients
older than 55 years who consulted their general prac-
titioner. When compared with the independent assess-
ment of two blinded clinicians, the questionnaire
showed a sensitivity of 91% and a specificity of 99%
for the diagnosis of 1e.5 Table 1 shows that the princi-
pal problem with questionnaires seems to be that they
are too rigorous (low sensitivity), therefore underesti-
mating the true prevalence of Ie. Furthermore, the
inaccuracy of any questionnaire probably varies
according to the age, occupation, and other character-
istics of the population to which it is applied. The con-
clusion is that one must be wary of any epidemiologi-
cal data based solely on questionnaires.
Clinical assessment
Although leg pain associated with exercise and relieved
by rest is suggestive of IC, it is not sufficient on its own
for a definite diagnosis. A detailed history taken by a
clinician will help to identify those patients whose leg
pain on exercise is attributable to another cause, for
example, nerve root compression or severe venous
insufficiency. However, the addition of a clinical exam-
ination does not necessarily eliminate the errors found
on questionnaires alone. False-positive rates of up to
44% and false-negative rates of up to 19% have been
reported after verification by noninvasive tests.s-'
The single most important part of the physical
examination to confirm a diagnosis of IC is palpation
of the patient's peripheral pulses . It must be remem-
bered, however, that an absent pulse may be attribut-
able to causes other than arterial disease. A prospec-
tive study of 1,000 children aged between 1 and 10
years were examined for the presence of dorsalis pedis
and posterior tibial pulses." The posterior tibial pulse
was invariably present, whereas the dorsalis pedis
was congenitally absent in 12% of the children. In
addition, the prevalence of absence of dorsalis pedis
was three times as high in white children compared
with black children. A further study by Ludbrook et
al? examined pulses in patients admitted to hospital
for noncardiovascular causes. In the 0- to 19-year
age-group, the posterior tibial and dorsalis pedis
arteries were absent in 0.2% and 8.7% of patients,
respectively?
At least one pulse is not detected in approximately
10% of the adult population when the femoral, poste-
rior tibial, and dorsalis pedis arteries are palpated.l?
However, 3% of these were asymptomatic (Figure 2).
At least part of the problem is observer error in detect-
ing pulses. Similar variability or reproducibility in the
detection of peripheral pulses was found in two stud-
ies in hospital patients.v" However, the authors of
these two studies reached very different conclusions..
In the first, they found that the agreement between the
observers improved during the study and reached
"satisfactory levels,"? and in the second, the authors
thought that there was "very great observer error,"
which did not diminish during the study."
It has been suggested that, for most ep idemiological
research, palpation of the peripheral pulses is proba-
bly too insensitive a measure of PAD. However, the
situation in general practice appears to be different.
The authors of a large general practice study in
Holland, in 2,455 patients with leg complaints, con-
cluded that palpation of both foot pulses is the key
procedure for the clinical diagnosis of PAD.l2 This
Eur J Vase Endo vasc Surg \'0119 Supplement A, June 2000
86 Epidemiology, Natural History, Risk Factors
enables the general practitioner to exclude the diagno-
sis in many patients with a high degree of certainty,
establish the diagnosis in a small group of patients,
and identify a limited group who require further non-
invasive testing. Figure 2 shows the interrelations
between intermittent claudication, pulselessness, and
ankle:brachial pressure index (ABPI) in 666 men and
women.
AI/kle: brachial pressllre index
For epidemiology purposes, the most useful noninva-
sive test is the ABPI. The Doppler ankle systolic pres-
sure has been shown to correlate closely with direct
intraarterial recordings.w'! The Doppler probe is also
easier to use than other techniques, such as plethys-
mography.15,16 The Doppler is very inexpensive; the
measurements are rapid, painless, and can be well
standardised.w Although it has been suggested that
strain-gauge plethysmography is more accurate than
the Doppler for ABPI, it is more difficult to use, and at
least one study suggests that it is no more repro-
ducible.'? It is generally recognised that the Doppler
systolic pressure may be inaccurate if the artery is not
compressible, as occurs, for instance, in some diabetic
patients. In addition, the use of ABPI measurement
depends on the brachial pressure being a true central
systolic pressure. This may not be the case in patients
with subclavian artery stenosis, which is most fre-
quent in diabetic patients and patients with CLI.
Intermittent
Claudication
n =25
46
ASPI < 0.9
n = 95
The variability in measuring ankle pressure has
been examined in several studies. tO,18.19.20,21 In one
study,'? ankle systolic pressure was found to vary in a
way similar to arm systolic pressure, whereas "good
reproducibility" was found in another study1 8 when
two successive measurements were made. Baker and
Dix19found that repeated measurements produced an
average range of 0.18 in the ABPI, and Carterv found
that 95% of repeat ABPI were within 9% of the aver-
age.22 The variability in both ankle systolic pressure
and ABPl measured on different occasions by different
observers appears to have only a marginal effect on
between-subject variability."
It has been suggested that a resting ABPI of 0.90 is up
to 95% sensitive in detecting angiogram-positive disease
and almost 100% specific in identifying apparently
healthy individuals.20.22,23.24.25,26 Although specificity in
the normal population is close to 100%, in patients with,
for instance, diabetes, the specificity will be less. Most of
these studies have used selected, symptomatic, hospital
patients and controls who were considered healthy
because they were young or had no signs or symptoms.
Individuals with vascular disease who had an angie-
graphically normal limb also were used as controls.
Thus, it is not known how ABPI in the general popula-
tion would correlate with angiographic findings in
PAD. However, results among those with severe dis-
ease likely would be similar to those found in hospital
patients. The Edinburgh Artery Study found an asso-
ciation between ABPI and disease severity in the gen-
eral population." Table 1 compares the sensitivity and
One or more
absent ankle pulse
n =70
Fig. 2. Interrelation between intermittent claudication, pulselcssness, and AOPI in 666 men and womcn.w
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Fig. 3. Incidence of Ie in men at different <lges in five population studies.
specificity of the various methods that have been used
to study the incidence and prevalence of IC and PAD.
It should always be remembered that the ABPI, or
indeed the palpation of pulses, assesses PAD, which is
not necessarily synonymous with Ie.
A 2.2.2
Incidence of Intermittent Claudication
Knowledge of the incidence and prevalence of IC is
essential for socioeconomic calculations and for health
care planning on both a regional and a national basis.
Estimates of the incidence of IC or PAD in a popula-
tion are subject to a number of errors. Only a minority
of patients with demonstrable PAD complain of symp-
toms of IC, whereas many patients with IC arc elderly
and consider that their symptoms are part of growing
old; therefore, they do not seek medical advice.
Patients' occupations and habitats greatly influence
the appearance of symptoms. Thus, the proportion
who consult their general practitioner varies from 10%
in the inner city30 to 50% in rural communities."
Because most of the patients who consult their physi-
cians are not referred to a specialist, incidences based
on hospital referrals are gro ssly underestimated.v
Although questionnaires enable a wider and less
selected population to be sampled, as already stated,
they tend to overdiagnose arterial disease.30;l1;l3.J.l;l3.36
Studies that focus on working populations also can
result in bias, for two reasons: First, the presence of the
symptoms may be related to the nature of the work.
Thus, IC has been found to be more common among
agricultural workers than in civil servants, Second,
individuals incapacitated by PAD may be automati-
cally excluded by the nature of their work. Figure 3
shows the incidence of IC in men at different ages in
various studies, with an obvious wide variation in the
absolute figures that can only partly be explained by
differences in methodology. It is interesting, however,
that the two studies of unselected populations that
also used ABPI measurements report the lowest inci-
dence of Ie. Within each study, there is a general pat-
tern of a gradual increase in incidence up to the age of
at least 60 years. Figure 4 shows the weighted mean
incidence of IC found in five large population-based
studies.
A 2.2.3
Prevalence of Intermittent Claudication
Many more studies have been done regarding the
prevalence rather than the incidence of Ie. However,
prevalence rates also differ depending on the study
population and the diagnostic methods used. Even
when the same diagnostic technique is used, this can
result in different prevalence rates, depending on the
age, sex, and geographic location of the population
studied. Thus, reported prevalence rates for IC using
the Rose questionnaire vary from 0.4% to 14.4%.32
Table 2 contains the larger studies using methodology
that is relatively reliable. Figure 5 summarises these
data.
In the Limburg study, 3,654 individuals aged 40 to
79 years were examined by their general practitioners,
and the diagnosis of IC was based on medical history,
clinical examination, and data from the patient's his-
tory,39 Independently of the general practice, the prac-
tice assistants assessed ABPI using a pocket Doppler
device and a mercury sphygmomanometer. An ABPI
of less than 0.95, measured twice within a week, was
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Fig. 4. Weighted mean incid ence of int ermittent claudication from five large population-based stud ies.
Table 2: Prevalence of Ie in men in large population studies
Study Location Population sample Age (yrs) Prevalence (%)
Hughson et aI, 1978" Oxford shire 1,716 45-69 2.2
De Backer et al, 19793:l Belgium 8,252 4D-49 0.8
5D-59 2.3
Reunanen et al, 198233 Finland 5,738 3D-39 0.6
4D-49 1.9
5D-59 4.6
Fowkes et al, 19914~ Edinburgh, Scotland 1,592 55-74 4.5'
Stoffers et al, 19913· Holl and 3,654 men & women 45-54 0.6
55-64 2.5
67-74 8.8
Smith et al, 199po Scotland 10,042 men & women olD-59 1.1
Novo et al, 1992" Palermo 1,558 men & women 4D-49 4.7
5D-59 9.2
"Overall prevalence for men and women aged 55-74 years: 4.5%.
considered evidence of PAD. An ABPI of less than 0.95
probably overestimates PAD. TI,e prevalence of PAD
in this study ranged from 1.4% for that diagnosed
using the strict Rose criteria to 1.8% for that diagnosed
by general practitioners and 6.1% when an ABPI of
less than 0.95 was used. Similar figures were obtained
from the Edinburgh Artery Study and the Scottish
Heart Health Study, using similar methodclogies.w"
The latter was one of the largest studies, over 10,000
subjects, to use clinical examination for diagnosing Ie.
The Finnish study was also similar in magnitude and
methodology as were the results.P The Oxford study
was unusual in that questionnaire-positive subjects
also had postexercise as well as resting pressure meas-
urements."
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In the larger, more reliable studies, there is a reason-
able consistency in the results; at around the age of 60
years, the prevalence of Ie in men is 3% to 6%. Figure
6 shows these results graphically, giving a rough idea
of the changing prevalence with age in men. Although
the prevalence in men is always greater than that for
women at all ages, no clear pattern emerges of any
changes in the ratio with age, with ratios varying from
a little oyer 1 to over 8 in one study.
Prcoalencc ofasymptomatic disease
The prevalence of asymptomatic disease can be esti-
mated only by using noninvasive techniques. The
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Fig. 5. Weighted mean prevalence of intermittent claudication in large population-based studies.
most widely used noninvasive test to detect asympto-
matic disease has been the measurement of ankle sys-
tolic pressures.lO,H,~~ The Basle studyv used pulse
waveforms detected by oscillography, and a USA
study also included a reactive hyperemia test."
Noninvasive diagnostic tests have not been widely
used in epidemiological surveys of PAD. The preva-
lence of asymptomatic disease in various studies
ranges from 0.9% to 22%, with the ratio of sympto-
matic to asymptomatic disease in individual studies
ranging from 1:0.9 to 1:6.0.4,IO.33.42,43,45,47,~S,49,50
The detected prevalence of asymptomatic PAD
largely depends on the measurement technique used.
This is well illustrated in Hiatt et al's careful study in
California.t! A resting ABPI of less than 0.9 is
believed to be associated with a 50% or greater vessel
stenosis and could serve as an arbitrary definition of
PAD. Detailed analysis of the available data suggests
that for every patient with IC there are probably
another three with asymptomatic disease causing a
50% or greater stenosis of the arteries supplying the
legs.
A 2.2.4
Risk Factors for Developing Intermittent Claudication
The risk factors for developing PAD are similar to
those for other atherosclerotic diseases. The influence
of age and sex in the incidence and prevalence of IC
has already been considered. A number of studies have
looked at other classical risk factors, such as diabetes,
hypertension, lipid abnormalities, and smoking, as
well as some more recently identified associations,
such as plasma fibrinogen levels, impaired glucose tol-
erance, and hyperhomocysteinemia.
Diabetes mellitusand impaired glucose tolerance
Many studies have shown an association between
diabetes mellitus and the development of
PAD.3~,H,52,53,5~,55,56,57,58,59 Overall, IC seems to be about
twice as common amongst diabetic patients as
among nondiabetic patients. Over the last decade,
mounting evidence has suggested that insulin
resistance plays a key role in the so-called meta-
bolic syndrome, which is characterised by the
coincidence of obesity, non-insulin-dependent dia-
betes mellitus, hyperinsulinaemia, hyperlipidaemia,
hypertension, hyperuricaemia, and cardiovascular
disease.w
Smokillg
The relationship between smoking and PAD has been
recognised since 1911,when Erb61reported that IC was
3 times more common among smokers than among
nonsmokers. Interventions to decrease or 'eliminate
cigarette smoking have therefore long been advocated
Eur JVase Endovasc Surg Vol 19 Supplement A, [une 2000
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for patients with K', It has been suggested that the
association between smoking and PAD may be even
stronger than that between smoking and coronary
artery disease (CAD).44.56.59,62In the Framingham study,
the risk at all ages was almost double for PAD com-
pared with CAD.3-I All epidemiological studies of PAD
have confirmed that cigarette smoking is a strong risk
factor for the development of Ie.10.31.33,3-IA3.53.55.56.63 In
addition, a diagnosis of PAD is made up to a decade
earlier in smokers than in nonsmokers.44lH,65
The severity of PAD tends to increase with the
number of cigarettes smoked.66,67,6s,69,io,71 Cigarette
smoking increased the risk of IC in both sexes, and
heavy smokers had a fourfold risk of developing Ie.3-I
It has been reported that smoking cessation is associ-
ated with a rapid decline in the incidence of IC and
that the risk of IC for ex-smokers 1 year after quitting
is approximately the same as that for nonsmokers.ev"
However, this is at variance with the results from the
Edinburgh study, which found that the relative risk
of IC was 3.7 in smokers compared with 3.0 in ex-
smokers (discontinuation of smoking for more than
5 years)."
Hypcrtcnsion
The Framingham study has provided the most con-
vincing epidemiological evidence of a link between
hypertension and PAD.3-I.53.55,56 Kannel and McGee3-1
Eur J Vase Endovasc Surg Vol 19 Supplement A, June 2000
showed that hypertension carried a 2.5-fold age-
adjusted risk in men and a 3.9-fold age-adjusted risk
in women. This is also suggested by the Edinburgh'!
and the Baslev studies but not by the Whitehall'? and
the Finnish» studies, which found no association
between PAD and hypertension. The discrepancy
between these results may in part be due to the com-
plex link between hypertension and Ie. Both are asso-
ciated with PAD, but hypertension is probably both a
cause and an effect of atherosclerosis. Finally, hyper-
tension may to some degree delay the onset of symp-
toms of IC a patient with PAD by elevating the central
perfusion pressure; it is not uncommon for a hyper-
tensive patient to develop IC when high blood pres-
sure is discovered and treated.
Haemaioiogic factors
Hyperlipidaclllia There is conflicting evidence regard-
ing the relationship between hyperlipidaemia and
PAD. In the Framingham study, a fasting cholesterol
level greater than 270 mg/dL (7 mmol/L) was associ-
ated with a doubling of the incidence of Ie. It appears
that the ratio of total to high-density lipoprotein
(HDL) cholesterol is the best predictor of occurrence of
arterial disease.P Although some studies have also
shown that total cholesterol is a powerful independent
risk factor for PAD,3-I,67 others have failed to confirm
this association.3IA7,~8,63,i~,i5It has been suggested that
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cigarette smoking may enhance the effect of hyper-
cholesterolaemia. There is evidence that treatment of
hyperlipidaemia reduces both the progression of PAD
and the incidence of lC. i 6,77 An association between
PAD and hypertriglyceridaemia has also been report-
ed, but the strength of this association is
unclear.IO,31,33,~A3,63 Hypertriglyceridaemia, however,
has been shown to be associated with the progression
and systemic complications of PAD.iS Recently,
Cheng> has shown that lipoprotein (a) (Lp[aj) is a sig-
nificant independent risk factor for PAD.
Fibrinogen An increased plasma level of fibrinogen
has been associated with PAD in several studies, and
other studies have established the role of high fibrino-
gen levels as a thrombotic risk.31,80,SI
HyperllOlllocysteillelllia The incidence of hyper-
homocysteinemia is as high as 60% in the vascular
population, compared with 1% in the general popula-
tion.S2,S3 It is reported that hyperhomocysteinemia
was detected in 28% to 30% of patients with prema-
ture PAD.S4,S5 The suggestion that hyperhomo-
cysteinemia may be an independent risk factor for
atherosclerosis has now been substantiated by several
studies.86.87,ss It may be a stronger risk factor for PAD
than CAD. A meta-analysis of studies concluded that
the odds ratios for CAD were 1.6 and 1.8 in men and
women, respectively, compared with 6.8 for PAD.89 It
also suggested that hyperhomocysteinemia may
account for 10% of the population risk for coronary
artery disease.
Hypercoaglllability Raised haernatocrit levels have
,been found in patients with IC and have been found to
be predictors of future graft occlusion.9o,91,92 However,
this increase may well be attributable to an association
with smoking. In the Framingham study, an elevated
haematocrit was not associated with a greater risk of
IC.~ In one study, Ray et al93 showed that the preva-
lence of hypercoagulabiIity in patients with stable
claudication was 25%, compared with 11% in the gen-
eral population. This increased to 40% in those
patients requiring vascular intervention.
Coexisting riskfactors
The coexistence of at least some of the above risk fac-
tors increases the risk of PAD at least additively in the
lower limbs. When cigarette smoking, diabetes melli-
tus, and systolic hypertension were considered in the
Basle study, the relative risk increased from 2.3 to 3.3
and 6.3 in those individuals with one, two, or three
risk factors, respectively." The Framingham study has
found similar results.v In particular, inclusion of ciga-
rette smoking dramatically escalates the risk of IC
when combined with any other risk factors (Figure 7).
Protective factors
Inevitably, the absence of a risk factor is protective.
However, other positive protective factors for the
development of IC have also been identified, includ-
ing moderate alcohol intake'" and a history of regular
physical activity.e
Risk of intermittent claudication
40
0
0
0
,.- 30
"-Q)
0-
Q) 20..-co
"-
"-co
Q) 10
>.,
co
0
Systolic BP 105
Serum Cholesterol 185
Glucose intolerance 0
36.6
14.6
150 195
260 335
o +
o Smoker
• Non-smoker
_ Average risk for
a 65 year old man
Fig. 7. Estimated probability of a 65-year-old man developing Ie with a specific blood pressure and cholesterol level and with, or without,
diabetes, based on a 26-year data from the Framingham study (Kannel and McGee, 1985").
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Genetic risk
Although a positive family history has been definitely
linked with coronary heart disease, increasing the risk
by 1.5- to 2-fold,97 and stroke,so,98 it has not been con-
firmed as a significant risk factor for PAD. Both the
Nurses' Health Study and the Framingham Offspring
Study found that a family history of CAD was an
independent risk factor for CAD in women.99,l 00 The
Danish Twin Concordance study found that that CAD
was higher in monozygotic twins compared with
dizygotic twins.r" An interesting prospective study by
Marenberg et al loo looked at 21,000 twins. The study
concluded that a family history of early death of coro-
nary heart disease is associated with an increased risk
of death of the disease and that at least part of this risk
was attributable to a genetic element.iw
A 2.2.5
Summary: Risk Factors for Developing Symptomatic
PAD
Figure 8 summarises the range of odds ratios for dif-
ferent risk factors. Excluding unavoidable factors, the
most important risk factors for developing sympto-
matic PAD are diabetes and smoking, with odds ratios
of approximately 2 to 3. Hypertension and lipid abnor-
malities are significantly less important, and the evi-
dence regarding their influence is more controversial.
A2.3
Coexisting Vascular Diseases
Because PAD, CAD, and cerebrovascular disease
(CVD) are all manifestations of atherosclerosis, it is
not surprising that the three conditions commonly
occur together. The extent of coexisting cardiovascular
disease must be appreciated to ensure that the physi-
cian treating IC will treat it in a true context. Studies
on the prevalence of CAD in patients with IC shows
that history, clinical examination, and electrocardiog-
raphy typically indicate the presence of CAD in 40%
to 60% of such patients, although this may be asymp-
tomatic if exercise is severely limited by claudica-
tion. 31,55,103,I 0-1,105,106,107,108,109,110,111,112,113,114,115,116
As with asymptomatic PAD, the diagnosis of CAD
depends on the sensitivity of the methods used. In one
study, in which coronary angiograms were performed,
the prevalence was as high as 90%.115 All patients pre-
senting to the Cleveland Clinic from 1978 to 1981 for
elective peripheral vascular surgery had cardiac
catheterisation to determine whether prophylactic
treatment of severe CAD could improve their long-
term survival. Only 10% of the 381 patients presenting
with IC had normal coronary arteries on angiography,
whereas 28% had severe three-vessel disease that mer-
ited revascularisation or was already inoperable. The
converse is also true: among individuals with CAD,
the prevalence of PAD is higher than in non-CAD
Odds ratio
Protective Harmful
-2 -1 0 2 3 4
Male gender (cf female) ~
Age (per 10 years) ~
Diabetes +
Smoking ~
Hypertension +
Hypercholesterolemia
•Fibrinogen +
Alcohol +
Fig. 8. Range of odds ratios for risk factors for developing intermittent claudication.
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Fig. 9. Number and percentage of patients with cardiovascular disease in subgroups with decreasing ABPI index (Newman et aI1l7) .
individuals.P-" The relative risk of IC among Finnish
men and women with angina pectoris compared with
controls was 7.2 and 3.9, respectively.v Aronow and
Ahn1l2 found that 33% of CAD patients also had PAD.
In the Cardiovascular Health Study, ABPI was closely
correlated to the number of patients with myocardial
infarction (MI), angina, and congestive heart disease
(Figure 9).117
The link between PAD and CVD seems to be
weaker than that with CAD. Although approxi-
mately half of all patients with IC have CAD
detectable by simple clinical techniques, a much
lower proportion have demonstrable CVD.31,94.112.118
By duplex examination, carotid disease has been
found in 26% to 50% of patients with IC.1l9.120.12I,122
Most of these patients will have a history of cerebral
events or a carotid bruit and seem to be at increased
risk of further events.t-' Aronow and Ahn1l2 found
that 33% of patients with CVD also had PAD. There
is very little reliable information on the overlap
between significant arterial disease in the three cir-
culations: leg, heart, and brain. Most studies have
concentrated on one area only and recorded only
superficially, if at all, the coexistence of significant
arterial disease elsewhere. The large CAPRIE study
of almost 20,000 patients is an example of this, in
which the presence or absence of claudication in the
patients enrolled after MI was based on a single
question.s- The other problem with the CAPRIE
study, from an epidemiological point of view, is that
the sizes of three populations of patients with PAD,
recent MI, or recent cerebrovascular accident
enrolled in the CAPRIE study were kept artificially
similar by the protocol.
A more realistic picture of the overlap between
PAD, CAD, and CVD is probably given by Aronow
and Ahn's prospective study in 1,886 patients aged
older than 62 years.u- CAD, PAD, and CVD (diag-
nosed by clinical history or electrocardiograph
[ECG]) were all more prevalent among men than
women. Only 37% of these patients had no clinical
evidence of PAD, CAD, or CVD. Figure 10 illus-
trates the overlap between PAD, CAD, and CVD in
these two studies. The evidence available from all of
the relevant studies suggests that approximately
60% of patients with PAD will have significant dis-
ease in the cardiac or cerebral circulation, and
approximately 40% of patients with coronary dis-
ease or significant cerebral circulatory disease will
also have PAD.
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Fig. 10. Overlap between PAD, CAD, and CVD in 1,886 patients aged >62 years. 37% of whom had no CAD, CVD, or PAD (adapted from
Aronow & Alm1l2 and CAPRIE62).
A2.4
Fate of Patients With Peripheral Arterial Disease
A 2.4.1
Fate of Local Disease in the Legs
Intermittent claudication can progress in four different
ways:
1. Improvement or stabilisation
2. Worsening claudication not requiring intervention
3. A need for intervention such as surgical revascular-
isation or angioplasty
4. A need for amputation
Worsening claudication
Although PAD is progressive in the pathological
sense, its clinical course is surprisingly benign in most
cascs .P' Large population studies provide the most
reliable figures. These include the Basle study findings
regarding the course of PAD, which are probably typ-
ical. This study documented angiographic progression
of the disease in 63% of patients 5 years after the ini-
tial diagnosis." However, of those who had survived
for 5 years after the diagnosis, 66% still had no limit-
ing Ie. Hospital-based series, even if essentially non-
surgical, tend to identify patients with IC who have
more severe disease or whose symptoms are progress-
ing. A recent multinational study, which recruited
patients predominately from nonsurgical hospital
clinics, showed that 6% deteriorated in terms of walk-
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ing distance over the first year.111 All of the evidence
over the last 40 years since the classic study by Bloor125
has not materially altered the impression that only
about a quarter of patients with IC will ever signifi-
cantly deteriorate. This symptomatic stabilisation may
be due to the development of collaterals, metabolic
adaptation of ischaemic muscle by an increase in aer-
obic enzyme content and capillary density, or the
patient altering his or her gait to favour nonischaemic
muscle groups. The conditions of the remaining 25%
of patients with IC deteriorate; this is most frequent
during the first year after diagnosis (7%-9%) com-
pared with 2% to 3% per annum thereafter.125,126
There is a wide variation in different series in the
proportion of patients with IC who ultimately require
intervention, from 3% 127 to 22%,100 which depends
largely on the type of claudicant enrolled in the study.
The lower figures are likely to be a truer reflection of
what happens to all patients with IC, because the
higher figures are mostly from centers to which more
severe cases have been referred. Bloor's reported
major amputation rates of 7% over 5 years and 12%
over 10 years have been supported by other studies
that also looked at selected populations several
decades ago.103,10U05 However, two more recent
reviews also highlight that major amputation is arela-
tively rare outcome of claudication, with only 1% to
3.3% of patients with IC needing major amputation
over a 5-year period.m.12s
This is likely to reflect an increase in successful limb
salvage procedures rather than a change in the local
progression of the disease. The Basle and Framingham
studies, which are the two large-scale studies that
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Fig. 11. Range of odds ratio s for risk factors for the progression of local d isease in the legs.
have looked at unselected patients, found that fewer
than 2% of PAD patients required major amputa-
tion .57,73 In summary, the existing data suggest that
only one fourth of all patients with IC deteriorate pro-
gressively, and with an intervention rate of approxi-
mately 5%, only 1% or 2% of all patients with IC will
ever need a major amputation. Although amputation
is the major fear of patients informed that they ha ve
circulatory disease of the legs, they can rest assured
that this is an unlikely outcome.
A 2.4.2
Risks Factors for the Progression of Local Disease in
the Leg
Primary risk factors for vascular disease in general
tend to be only weak secondary risk factors in patients
with Ie. Figure 11 summarises some of the studies that
have looked at the magnitude of the risk for the pro-
gression of local disease with various risk factors.
Smoking
Smoking is the most important risk factor that can be
influenced . Cronenwett et al129 found that patients
with IC who had smoked at least 40 pack-years
required reconstructive vascular surgery over three
times more frequently than those who had smoked
less. The most extreme example is the study by
Juergens et al,13° who reported a major amputation
rate of 11% in patients with IC who smoked compared
with no major amputations in nonsmokers.
Diabetes
PAD in patients with diabetes is more aggressive, with
early large vessel involvement coupled with microan-
giopathy. McDaniel and Cronenwett'> showed that
patients with IC and diabetes had a 35% risk of sud-
den ischaemia and a 21% risk of major amputation,
compared with 19% and 3%, respectively, in nondia-
betic patients. Two other studies have also found
increa sed major amputation rates in patients with IC
and diabetes.131,m Similar results were found by
Dormandy and Murray and Ielnes et al. lII ,l26
ABPI
In a prospective trial in nearly 2,000 patients with IC
whose entry characteristics were analysed to look for
predictors of deterioration of PAD (eg, need for arte-
rial surgery or major amputation), the most signifi-
cant predictor was an ABPI less than 0.5.111 This car-
ried a relative hazard ratio of 2.3, a finding similar to
that of [elnes et al,126who found that a low ABPI was
Eur J Vase Endovasc Surg Vo119 Supplement A, June 2000
816 Epidemiology, Natural History, Risk Factors
associated with a relative risk of 2.4 for local pro-
gression. Over the 6.5-year follow-up in this study,
no major amputations were required in patients with
an initial ankle pressure greater than 70 mm Hg,
although the proportion of patients with diabetes
was unusually small (5.4%).126 Several studies have
indicated that in those patients with IC in the lowest
strata of ankle pressure (ie, 40-60 mm Hg), the risk of
progression to severe ischaemia or actual limb loss
was 8.5% per annum,126,133,13-I.135 whereas one of the
studies showed a clear stepwise correlation between
outcome and decreasing ankle pressure.126There is a
suggestion that claudication has a more benign
course in women. In most of the large population
studies of prevalence, there was a male:female ratio
of approximately 2:1 for patients with IC, compared
with ratios of 3:1 to 13:1 in series studying the disease
at a later stage.36,I03,I07,125,131,132 Dormandy and
Murray'!' found that men had a relative risk of 1.66
for deterioration of leg ischaemia compared with
women.
Hupertension
Although Jelnes et al126noted that the risk of deterio-
ration was related to systemic arterial pressure, the
study by Dormandy and Murray,"! which included
patients on antihypertensive medication, and which
performed a multivariate analysis to correct for the
presence of other risk factors, found that hypertension
did not influence the local progression of PAD.
A2.5
Progression of Systemic Atherosclerosis
The evidence for coexisting arterial disease in patients
with PAD has already been reviewed. Patients with
either asymptomatic or symptomatic PAD generally
have widespread arterial disease and therefore have a
significantly increased risk of stroke, MI, and cardio-
vascular death. PAD should therefore be viewed as a
sign of potentially diffuse and significant arterial dis-
ease. Recent reports show a 1% to 3% annual incidence
of nonfatal MI.1I1,128 The Edinburgh Artery study has
shown that patients with IC have a significantly
increased risk of angina (relative risk, 2.31) whereas
asymptomatic PAD patients have a slightly increased
risk of MI and stroke.P? The frequency of these events
seems to be correlated with PAD severity, as assessed
by ABPI or the presence of popliteal trifurcation dis-
ease. 1I1,138 Indeed, Ogren et al1l8found that anABPI less
than 0.9 was the best predictor of stroke in 68-year-old
men with asymptomatic carotid stenosis. Table 3 sum-
marises the limited information about the incidence of
nonfatal cardiovascular events in patients with IC
There seems to be general agreement that between 2%
and 4% of patients with IC have a nonfatal cardiovas-
cular event within the first year.
A 2.5.1
Mortality
In the 1950s, Allen et aIm stated that half of the exist-
ing patients with IC would be dead within 5 years,
Table 3: The incidence of nonfatal cardiovascular events in patients with intermiUent claudication
Study No of patients
Bloor, 1961123 1,476
Begg& Richards, 1962 1().l 198
Peabody et al, 1974 139 162
Kallero et al, 1985
'
3:3 368
Widmer et al, 1986 110 236
Gilliland et al, 1986' 18 400
Dormandy & Murray, 1991111 1,969
Davey Smith et a!' 1991'~1 18,403
Leng et al, 1996137 1,592
CAPRIE, 1996·~ 19,185
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and Stammers'P added that those aged 55 to 60 years
would die of CAD within 5 years. Although these
opinions now seem overly pessimistic, they show an
appreciation of the higher mortality rate of patients
with symptomatic PAD. Bloor125 estimated that a clau-
dicant's life expectancy was decreased by 10 years.
Despite disparity in patient selection, over two dozen
studies show some degree of agreement about the
overall mortality in those with Ie. The 5-, 10-, and 15-
year mortality rates from all causes are approximately
30%, 50%, and 70%, respectively-an outlook that is
not much better than that following resection of a
Duke's B carcinoma of the colon. This emphasises
most clearly that the real danger for the patient with
symptoms of leg ischaemia, intermittent claudication,
is not losing the leg but rather suffering premature
cardiovascular complications or death. Both patients
and their physicians should therefore give therapeutic
priority to the latter.
The Coronary Artery Surgery Study (CASS) com-
pared survival in 2,296 patients with PAD and 13,953
controls. Patients with PAD were found to have a 25%
greater likelihood of dying compared with those with-
out (hazard ratio, 1.25).1-14 ABPI has also been correlat-
ed with mortality in two studies.6•H 5 In the first study,
with 1,492women older than 65 years, the 4-year mor-
tality rate in those with an ABPI greater than 0.9 was
9.5%, compared with 53.7% in those with an AI3PI of
0.9 or less.s Similar results were found in the second
study, in 1,537 men and women older than 60 years,
which found mortality rates after 1 to 2 years' follow-
up of 1.7% in those with an ABPI greater than 0.9 and
6.9% in those with an ABPI of 0.9 or less.!"
Of particular interest are the studies in which the
difference in mortality rates between claudicant and
nonclaudicant patients was adjusted for differences
in known risk factors such as smoking, hyperlipi-
demia, and hypertension. Such risk factors would be
expected to be commoner in and contribute to a
higher mortality rate in patients with fC, The
increased risk of death in claudicant patients was
largely unchanged despite the adjustment for risk
factors. These surprising but consistent results sug-
gest that there may be a special, as yet unidentifi-
able, risk factor in patients with IC other than simply
atherosclerosis. Figure 12 pools the results from all
studies comparing mortality rates of claudicant
patients with those of a matched nonclaudicating
population. As expected, the two lines diverge
steadily at a constant slope, indicating that on aver-
age the mortality rate of claudicant patients is 2.5
tim es that of nonclaudicant patients.
A 2.5.2
Cause of Death in Patients With Intermittent
Claudication
Although CAD is by far the most common cause of
death among patients with PAD, the proportion is still
surprisingly low (40%-60%), with CVD accounting for
10% to 20% of deaths. Other vascular events, mostly
ruptured aortic aneurysm, account for approximately
10%. Thus, 20% to 30% of patients with PAD die of
noncardiovascular causes (Figure 13).
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Fig.13. Cause of death in patients with IC and in the general population in Germany in 1996 (source: Federal Stalistical Office of Germany).
A 2.5.3
Summary: Fate of the Claudicant
Figure 14 summarises the fate of the claudicant, which
is relatively benign as regards local disease in the leg,
but which is increasingly malignant in terms of fatal
and nonfatal serious cardiovascular events. Only
approximately 5% of patients with IC need surgical or
endovascular intervention over 5 years for either
severe claudication or deterioration to critical limb
ischaemia. Approximately 2% of patients with IC ever
need a major amputation.
A 2.5.4
Risk Factors for Systemic Morbidity or Mortality
Not surprisingly, the presence or absence of severe
CAD seems to determine a claudicant's fate.
Dormandy and Murray found that patients with IC
and CAD were twice as likely to die as those without
CAD.111 Both Begg and Richardsw' and Juergens et a1l3O
noted that claudicant patients with clinical or electro-
cardiograph evidence of coronary ischaemia had sur-
vival curves similar to those who had survived an MI.
Because low ABPI «0.5) has been shown to be relat-
ed to the severity of CAD, it is not surprising that this
index has also been associated with an increased mor-
tality risk.s McDermott et all46 have shown that the
ABPI is a powerful tool for predicting survival in
patients with PAD; patients with an ABPI of 0.3 or less
had a significantly poorer survival rate than those with
an ABPI of 0.31 to 0.91 (relative risk, 1.8).A recent study
has shown that, in multivariate analysis, hypertriglyc-
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eridaemia (2:2 mmol/L) was the only independent fac-
tor associated with deterioration of ABPI (relative risk,
1.8) and with the onset of CLI (relative risk, 1.9),78
SmokingW.H8.H9 diabetes,I05.106.I07,108,109,111,126.W hyperten-
sion,I04.111.126 white cell count,111.148 asymptomatic carotid
disease.w and fibrinogenH8.151 have all been reported as
predictors of mortality. Smoking increases mortality
rates among patients with IC by between 1.5 and 3.0.5
Figure 15 illustrates the odds ratios for different risk
factors; it is interesting that diabetes and smoking seem
to be less of a risk for total mortality than for progres-
sion of local disease in the legs (see Figure 11). The ABPI
seems to be a far better predictor of all-cause mortality
in these patients.
A2.6
Critical Limb Ischaemia
Critical limb ischaemia (CLI) is the term used to
delineate those patients whose arterial disease has
resulted in a breakdown of the skin (ulcer or gan-
grene) or pain in the foot even at rest. It therefore
coincides with stages III and IV of the Fontaine
classification. This equates to the Rutherford 4, 5,
and 6 categories of the New SVS-ISCVS
Recommendation of Reporting Standards.tv The
principal reason for adopting this broad inclusive
definition is that most of the epidemiological data
relate to this whole group. It is not possible to talk
about the natural progression of these patients
because they inevitably require active intervention.
Although numerically far less than patients with
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Fig. 14. Five-year fate of the claudicant.
IC, patients with CLI demand a disproportionately
large commitment both in medical effort and eco-
nomically. They also represent the major workload
for vascular surgical units. However, it is only
much more recently that data have been collected
on large series of CLI patients outside the context of
specific surgical procedures.
A 2.6.1
Incidence and Prevalence of eLi
There is little direct information on the incidence of
CLI. Catalano's' assessed its incidence in North Italy
using three different approaches. First, a prospective 7-
year study on the incidence of CLI in 200 patients with
IC and 190 controls (development); second, a prospec-
tive 3-month study of hospitalisations for CLI in a sam-
ple of hospitals in Lombardy (hospitalisations); and
third, encoding the major amputations performed in
the hospitals in two regions (Lombardy for 6 months,
Emilia Romagna for 2 years) (major amputations). The
results from the three approaches were substantially
equivalent in order of magnitude (Table 4).
Based on a national survey, the Vascular Surgical
Society of Great Britain and Ireland concluded that
there were 20,000 patients with CLI in the population,
an annual incidence of 400 per million per year. l54 The
incidence of CLI can also be extrapolated from the bet-
ter-documented prevalence studies of Ie. If one
assumes that the overall prevalence of claudication is
3% and that 5% of patients with IC will develop CLI
over 5 years, this gives an incidence of CLI of 300 per
million per year. Finally, the incidence of CLI can be
calculated from the number of major amputations per-
formed (Table 6). Assuming that 90% of major ampu-
tations are performed for ischaemia and that only 25%
of patients with CLI ever require a major amputation,
it can be calculated that the incidence of CLI is approx-
imately 500 to 1,000 per million per year. Surprisingly
perhaps, the incidences calculated using these differ-
ent methodologies are very similar. Roughly, one new
patient per year will develop CLI for every 100
patients with IC in the population.
Table 4: Incidence of CLI and major amputations in the population aged >45 years in Northern Italy using three different approachestv
Incidence of CLI
(per million per year)
Incidence of major amputations
(per million per year)
Development of CLI
Hospitalisations for CLI
Major amputations
Lombardy
Emilia Romagna
450
652
577
530
112
160
172
154
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A 2.6.2
Risks Factors for the Development of Critical Limb
Ischaemia
The risk factors for the development of CLI are exact-
ly the same as those for the progression of local dis-
ease, the most important, apart from age, being smok-
ing and diabetes.
Age
As already stated, the prevalence of PAD increases
rapidly with age, as does the hospital admissions
rate.v Major amputations are also more common in
the elderly. In a 3-year prospective study of lower limb
major amputations in Malmohus county in Sweden,
45% of the amputees were at least 80 years 01d.155In a
Danish national discharge survey in 1980, the inci-
dence of lower limb major amputations increased
from 0.3 per 100,000 per year for those younger than
40 years, to 226 per 100,000 per year for those older
than 80 years.I56
Smoking
Cigarette smoking increases both the risk of develop-
ing PAD and its progression. The risks associated with
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smoking apply to all ages and increase with the num-
ber of cigarettes smoked.J29 In multivariate analyses,
smoking has been shown to be an independent risk
factor6-1,9U55and to be more important in causing PAD
than CAD.9~ Major amputation is more common
among patients with IC who are heavy smokers'F and
who continue to smoke.w
Diabetes
Diabetes mellitus affects 2% to 5% of Western popu-
lations. However, 40% to 45% of all amputees are
diabetic. Therefore, diabetic PAD patients are
approximately 10 times more likely to need an
amputation than nondiabetic PAD patients. The
Basle study reported that major amputations were
11 times more frequent in diabetic PAD patients
than in nondiabetic PAD patlents.?' One study
reported the progression of CLI to gangrene to be
40% in diabetic patients compared with 9% in non-
diabetic patients.v The correlation between diabetes
and major amputation rates is independent of other
risk factors, including age and smoking.t>'
However, smoking does appear to have an additive
effect.15s Those with diabetes generally undergo
major amputations at an earlier age than those with-
out diabetes.159,16o,161
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A 2.7
Fate of Patients With Critical Limb Ischaemia
It is no longer possible to describe the natural history
of the critically ischaemic limb, because most patients
now undergo some form of arterial reopening proce-
dure. Table Sa shows the mortality rates in some large
series of patients, most of whom newly presented with
CLI to a vascular surgical center. It is interesting to
note the variation in the proportion of patients where
some form of revascularisation was attempted. In
some highly specialised and aggressive units, 90% or
more of the patients had an attempted revascularisa-
tion. The primary amputation rate varied from
approximately 10% to approximately 40%. The
remaining patients had general supportive and med-
ical treatment only. The studies in Table Sa are mostly
from single centres. Perhaps a better picture of what
happens to an average patient who develops CLI
would come from multicentre audit data. Some exam-
ples of these are shown in Table 5b.
More recently, several studies have reported the fate
of patients with recently diagnosed CLI after 1- and 2-
years' follow-up. Wolfel62 in Britain has reported 1-
year mortality rates of around 20% in unselected
patients with CLI, while a study in Zurich found a
similar proportion dying over 6 months.w In a
prospective observational study in Italy, 574 patients
were recruited in 69 centres mainly on the basis of
clinical findings of CLI (rest pain and/or trophic
lesions). At the end of three months, 50 (8.7%) patients
had died, 3 (0.5%) had an MI, 6 (1.0%) a stroke, 70
(12.2%) a major amputation, while 103 (17.9%) had
persistent CLI. In a subsequent follow-up report 21.9%
(121/552) were dead at 1 year, while an additional 44
(11%) died during the second year, giving an overall 2-
year mortality of 31.6%.1~ As expected, the overall
incidence of vascular deaths was much higher than
that for non-vascular deaths (34.5 vs 8.5%, respective-
ly). Cardiovascular deaths were also relatively higher
at the end of the first (36.4 vs 6.6% respectively) than
at the end of the second (29.5 vs 13.6%, respectively)
year of follow-up.t-'
Finally, there are some good-quality data from multi-
centre, closely monitored trials of pharmacotherapy
for CLI. These are summarised in Table 5c.
Unfortunately, these data only relate to a subgroup of
patients who are completely unreconstructable or in
whom attempts at reconstruction have failed. It is only
such patients who are entered into randomised, place-
bo-controlled clinical pharmacotherapy trials.
Information about the spontaneous course of CLI can
therefore be deduced from those patients who receive
placebo. The results for this subgroup reveal the
appalling prospect that approximately 40% will lose
their leg within 6 months, whereas up to 20% will
die,176.177.178.179 In most of these studies, less than half of
the patients were alive without a major amputation
after 6 months.177,178.179 De Weese and Roblo;found that
virtually all (95%) patients who presented with
ischaemic gangrene and 80% of those presenting with
rest pain were dead within 10 years.
A2.8
Changing Outcome of Critical Limb Ischaemia
There is an ongoing controversy, often fueled by
unverified retrospective audit data from large and
changing populations, as to whether there is a signifi-
cant reduction in amputations as a result of more vas-
cular reopening procedures in patients with CLI.I80,181
A recent, particularly careful, study of a fixed popula-
tion in Sweden over 8 years strongly suggests that a
decrease in primary amputation (from 42% to 27%),
associated with a corresponding increase in revascu-
larisations, resulted in an overall decrease in amputa-
tions from 61% to 47%.182 In the United Kingdom, the
number of major amputations has reached a plateau,
possibly reflecting increasingly successful limb sal-
vage.l83 A decline in major amputation rate has also
been reported in Denmark: from 34.5/100,000 in 1983
to 25/100,000 in 1990.1&1 Between 1981 and 1990 in
Scotland, the major amputation rate fell by 22%.185
However, this study highlighted incon sistencies with-
in different age-sex groups. Thus, in the population
younger than 65 years, the major amputation rate
decreased by 45%, whereas in those older than 65
years, it increased by 54%.
Major amputation rates also decreased in men, but
there was a paradoxical increase in women. During
the period of this study, the reduction in major ampu-
tation rate was accompanied by a doubling of the rate
of arterial reconstructions, with an increase in all
age-sex groups. In Western Finland, Luther reported a
22-year (1970-1991) retrospective survey of surgical
patient data compared with population data, which
showed a 2.5-fold increase in major amputations from
1970 to 1991.I86 Figure 16 summarises in diagram form
the initial overall treatment of all patients presenting
with CLI, and Figure 17 summarises the data from
studies looking only at "end-stage" CLI, those patients
who are unsuitable for revascularisation or in whom
revascularisation has failed and cannot be repeated
(Table 5c).
Allowing for the different periods of follow-up, it is .
surprising that the fate of the patients with CLI who
have just presented and are considered for primary
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Table 5: Fate of patients with critical limb ischaemia
No patients/
limbs
Attempted
re-vascular-
isation(%)
Primary
amputation Follow-up Mortality
(%) (yrs) rate (%)
Alive Alive
with without
persistent amputation
CLI (%)
Ampu-
tation
(%)
a) Surgical series
McGrath et al,m 1983 2,064 22.6 4.2
Ouriel et 011, 165 1988 362 56.3 43.6 3 71
Griffith and Callum,"61988 402 67.1 36.8 2 50
28
Holdsworth,1671997 319 43 18 1 12 (amp) 51
8 (revasc)
Veith et al,If" 1981 755 89.9 10 5 52
Taylor et 011,169 1991 627 97.2 2.8 1.95 2.3 7.0
Hickey et al, ~09 1991 315 88 14.2 5 41
b) Multicflltrcseries
Wolfe, 162 1986 409 61 7 1 18 26
ICAI Group,l6-l 1997 522 44.4 9.4 2 31.6 55 13.8 13.8
c) Ullrecollstrllctable or primaryfailed reconstruction
Tonnensen et 011,170 1978 21 19
Lowe et 011,176 1982 13 30.7 23 6mo 23
Belch et al,m 1983 13 7.69 6mo 23 53.8 15.4
Schuler et al,17I 1984 63 9.52 14.2 2mo 4.7 14.3
Telles et 011,172 1984 17 29.4 1 mo. 29.4
Norgren ct al,1781990 52 44.2 6mo 31 43.4
Bliss et 011, 179 1991 71 6mo 11 42 46.4
Balzer et al,t73 1991 58 1 mo
Guilmot & Diot,m 1991 41 3 19.5
Lcpantalo & Matzke.F? 1996 105 (136) 12 54 19.5
reconstruction is not much better than that of patients
in whom reconstruction is impossible or has failed.
A2.9
Major Amputation
A 2.9.1
Incidence and Prevalence of Major Amputation
The concept of patients who have a poor outcome,
steadily progressing through increasingly severe clau-
dication to rest pain, ulcers, and ultimately amputa-
tion, is incorrect. As already pointed out, an acute
onset of CLI carries a particularly bad prognosis. In a
recent study, it was found that more than hairof 713
patients having a below-knee major amputation for
ischaemic disease had no symptoms of leg ischaemia
as recently as 6 months prevlously!" In 1986 in
England and Wales, nearly 5,000 new patients were
referred for prosthesis fitting after major amputations
for CLI.ISS There are no accurate data on the number of
patients in the United Kingdom undergoing major
amputation without referral for a prosthesis but, using
the figures available for progression of claudication,-
total major amputations may be in excess of 15,000 per
annum (300 per million per annumj.t'" This compares
with estimates of 500/million population/annum in
Sweden.l?" 250/million/annum in Denmark.ts' and
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280/million/annum in the United States'?' (Table 6).
In Holland, Hoogcndoomt'? has reported on the major
amputation rate according to the level of major
amputation.
A 2.9.2
Risk Factors for Major Amputation
Although not substantiated by an adequate prospec-
tive study, the presence of gangrene and ulceration
(Fontaine IV), but not necessarily the size or number
of ulcers, seems to be associated with a poorer prog-
nosis than rest pain alone (Fontaine III).193 In the Joint
Vascular Research Group in Britain study,J62 patients
with CLI who had gangrene or ulceration were twice
as likely to require a major amputation as those with
rest pain alone. Juergens et alt30 noted a 5-fold increase
in a similar group over a 5-year period. Several stud-
ies have shown that survival without amputation in
CLI patients is related to ABPLH6,194,195 This is not sur-
prising; ABPI has already been shown to be one of the
most accurate predictors of mortality in claudicant
patients (see also A 3.2.3, Criteria for Success, p S32).111
The precise magnitude of the effect and whether it is
similar in patients with rest pain alone and those who
also have trophic changes has been much debated.
The Joint Vascular Research Group in Britain'< found
that there were significantly (p < 0.01) more viable legs
at 1 year among those patients with CLI who had rest
Cured
25%
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Fig. 16. The fate of patient s with CLI.
Fig. 17. Outcome at 6 months in patients who were either unsuitable for, or who failed, revascularisation.
523
pain (Fontaine III) and an ankle pressure greater than
40 mm Hg compared with those with rest pain and an
ankle pressure less than 40 mrn Hg . This differentia-
tion, however, was lost in those patients with ulcera-
tion or gangrene (Fontaine IV). It was therefore con-
cluded that although ankle pressure was a predictor in
eLI patients with rest pain alone, it was of little addi-
tional value in those patients with ulceration and
gangrene.
Level of nIIlpll In Iion
A review of 16 reports over the last 30 years shows
that the ratio of below-knee (BK) to above-knee (AK)
amputation is usually near 1 and has not changed
over the years.1%.197.198.199,200,201,202,20J,20-l,205.206.207,208.209,2IO,211
A more accurate picture of the changing pattern of
amputation may be obtained by looking at longitudi-
nal studies from the same centre. In one series, the
introduction of an aggressive team approach to ampu-
tation increased the BK-to-AK ratio from an unusual-
ly lowOl-; to 2.1.198 Data from published series look-
ing at the delayed healing and revision rates for BK
amputations show that primary healing ranged from
30% to 92% (mean, 70% to 75%)187.197,198.20J.20-l.205.21UIJ.lli
and the re-amputation rate from 4% to 30% (mean,
15%).20S.210.2tI ,215.216,217,218 Approximately another 15%
had delayed or secondary healing, which, in some
cases, required debridement and further procedures
such as wedge excision in an attempt to maintain leg
length.219,22o,221,222,223 Of the 30% of BK amputees whose
wounds do not heal primarily, approximately half will
need a higher major amputation.W ,lli,226,227,228 Less
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Table 6: Estimated number of major amputations/annum in different countries
Country Estimated number/million/annum
Dormandy & Ray, 1996' 39
Norgren, 1990190
Ebskov et al, 199·118-1
Kacy et al, 1982191
Hoogendoorn, 1988192
PeIl et al, 1994133
Luther, 19941S6
UK
Sweden
Denmark
USA
HolIand
Scotland
Western Finland
300
500
250
280
246
142
120
blood flow is required to keep tissues healed than to
achieve healing, and Kihn et al197reported that once a
BK major amputation healed, only 4% of such patients
ever require a higher amputation.
Data from 51 hospitals in six European countries
were collected regarding 713 patients requiring a BK
arnputatlon.t" In this study, at 3 months, 59% of
stumps had healed, 19% required an amputation at a
higher level, and 11% remained unhealed. The sur-
geons' assessment of the likelihood of healing was
wrong in 21% of cases in which the operating surgeon
believed that healing would occur. It was also wrong
in 52% of cases in which it was thought that healing
would not occur. Similarly, it is generally believed that
increasing the proportion of BK to AK amputations
must inevitably lead to a higher failure rate. Neither of
these beliefs is borne out by comparative studies of the
literature.
A 2.9.3
Fate of the Amputee
Two to three times as many BK amputees achieve full
mobility compared with AK amputees, and there has
not been any dramatic change in 20 years. I96,I99,205,215,217
Initial rehabilitation may take up to 9 months, but by
2 years, 30% of amputees are not using their prosthe-
ses.t96Older patients, women, and bilateral amputees
are particularly bad at mobilising.196,lli Kihn et a1l96
noted that only 25% of amputees had palpable foot
pulses in the contralateral limb and that, over a 2-year
period, approximately 15% required contralateral
major amputation. Although the need for major
amputation was related to the absence of distal pulses,
10% of the amputees with palpable contralateral foot
pulses also lost that foot within 2 years. Early hospital
mortality rates after BK amputation range in most
series from 3% to 10%, whereas the hospital mortality
after an AK amputation is nearer
20%.196,193,201,202,203,205,207,212,215,217,224,228,229 It is unlikely that
this increased mortality rate is directly due to the
higher level of amputation. Rather, it is due to the
selection of the older and "high-risk" patients, who
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have little prospect of rehabilitation, for what is con-
sidered a more reliable procedure in terms of primary
healing, and the fact that they have more widespread
arterial disease. However, several reports have related
operative mortality to coexisting medical conditions,
such as diabetes and cardiovascular, cerebrovascular,
and respiratory disease and found no significant cor-
relation.196,2os This difference is maintained for up to 2
years, when mortality rates of 25% to 35% for BK and
45% for AK amputees are seen.190,195,193,215
A 2.9.4
Summary: Major Amputation
Figure 18 summarises the fate of the BK amputee. Five
years after a BK amputation, 30% will have had a
major contralateral amputation, 50% will be dead, and
only 20% will be alive with one intact leg.
The nature of the onset of CLI may also be impor-
tant. Between 30% and 70% of patients who develop
acute CLI require major primary amputation, possibly
because they tend not to be treated in specialist cen-
ters, and because patients with acute CLI will not have
had the opportunity to develop collaterals.tv
A2.10
Conclusions
There are still surprisingly little good epidemiological
data on PAD compared with CAD or CVD. It is, how-
ever, clear that the prevalence of symptomatic and
asymptomatic PAD is greater than previously
thought. Both groups carry a high risk of death or
morbidity because of vascular disease in other territo-
ries. CLI is much rarer but carries an even worse prog-
nosis, in terms of both morbidity and mortality, which
is comparable to some of the most malignant cancers.
The current treatment modalities, in terms of either
preventing progression of local disease in the legs or
modifying the high mortality, are not particularly
successful.
Early
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After 2 years
S25
1° healing
60%
; Perioperative
; death 10%
Full mobility
. 40%
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amputation15%
Figure 18: Early and 2-year fate of the below-knee amputee (from Dormandy & Ray).
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A3
OUTCOME ASSESSMENT METHODOLOGY IN
PERIPHERAL ARTERIAL DISEASE
A3.1
Impetus for Outcomes Research
Although the value of lifesaving therapies is boldly
displayed in both the medical and lay press, most
medical treatment provided in the developed coun-
tries is directed toward improvement in quality of life.
. Interventions for claudication and eLI are examples of
therapies directed toward the relief of symptoms and
improvement in quality of life. The goal of all such
interventions is to reduce the adverse impact of an ill-
ness or disorder on the patient's life and improve the
patient's sense of well-being and productivity. As the
costs of health care continue to spiral upward, gov-
ernments and third-party payers are seeking to con-
tain costs by limiting reimbursement to those thera-
pies proven to be effective, either in saving lives or
improving quality of life. Ultimately, the decision to
advocate a treatment, and the decision by payers and
regulatory bodies for reimbursement involves a trade-
off between the additional costs incurred and effec-
tiveness gained by performing that treatment.'
Multiple studies have been published reporting the
experience of centres on the short and long-term
results of performing interventions for PAD.
